Patents Assigned to FRED
  • Publication number: 20120096590
    Abstract: The present invention provides methods for modulating the growth and/or yield of plants. In particular the methods comprise the use of agents which functionally inhibit the expression of plant D-like cyclin inhibitors including isolated polynucleotide sequences which interact with DNA or RNA encoding proteins capable of binding plant D-like cyclins. Further, the present invention provides recombinant polynucleotide sequences, vectors and host cells which encode proteins capable of binding to and inactivating the activity of plant D-like cyclin/cyclin dependent kinase complexes preventing plant cells from exiting the cell cycle. Methods for determining and agents which are inhibitors of the BRO cyclin dependent kinase inhibitor proteins which are capable of modulating plant cell cycle progression are also provided. Methods for the production of transgenic plant cells and plants with increased growth rates and yields when compared to wild-type plants are also provided.
    Type: Application
    Filed: November 21, 2011
    Publication date: April 19, 2012
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: James M. Roberts, Beth L. Kelly
  • Publication number: 20120027789
    Abstract: The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV, The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
    Type: Application
    Filed: April 3, 2010
    Publication date: February 2, 2012
    Applicants: Fred Hutchinson Cancer Research Center, University of Washington
    Inventors: Lawrence Corey, Kerry J. Laing, Anna Wald, David M. Koelle
  • Patent number: 8101155
    Abstract: The amino acid sequence of the heavy chain polypeptide and the light chain polypeptide of the STRO-1 antibody is disclosed. Also disclosed are methods for detecting and isolating cells expressing the STRO-1 cell surface protein.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: January 24, 2012
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Beverly Torok-Storb
  • Patent number: 8071377
    Abstract: The present invention provides methods for immortalizing precursor cells that are non-terminally differentiated cells such as stem cells, said methods comprising culturing the precursor cells in the presence of a Notch agonist and one or more growth factors that support the proliferation but not differentiation of the non-terminally differentiated cells. The present invention further provides methods to induce the differentiation of immortalized cells, comprising growing the cells in the presence of a Notch agonist and at least one growth factor which supports the differentiation of the cell into a more specialized cell type. The immortalized and/or differentiated cells of the invention can be used to repopulate cell populations that have been diminished, for example as a result of infection or exposure to certain drugs.
    Type: Grant
    Filed: July 15, 2008
    Date of Patent: December 6, 2011
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Irwin D. Bernstein, Barbara Varnum-Finney
  • Publication number: 20110295619
    Abstract: The present invention relates to systems for collecting patient data and for analysing the data for the purpose of managing patient assessment procedures. In particular, the invention relates to a system for using collected patient data for the purpose of prioritising patients for assessment by clinicians. In particular, the invention provides a system for analyzing patient data in an automated system for managing patient assessment. The system includes a database for storing patient assessment data collected from a plurality of patients, a computer processor executing instructions stored in a computer program and a data processing computer program executed by the computer processor.
    Type: Application
    Filed: May 25, 2011
    Publication date: December 1, 2011
    Applicant: FRED BERGMAN HEALTHCARE PTY LTD
    Inventor: Mark Tough
  • Publication number: 20110294217
    Abstract: An engineered highly specific DNA-cleavage enzyme delivers a site-specific nick in a double stranded DNA, to cleave one DNA strand within its target site while leaving the opposing DNA strand intact. The engineered enzyme provides the ability to induce a gene conversion event in a mammalian cell. An engineered sequence-specific nickase derived from a LAGLIDADG homing endonuclease is altered by a single amino acid residue, wherein the amino acid residue is involved in the polarization of solvent molecules and acid-base catalysis in the active site without affecting direct contacts between the enzyme and either the bound DNA or bound metal ions. Engineered, site-specific nickase variants, such as of I-AniI and other homing endonucleases, are particularly useful in targeted genome engineering as well as therapeutic, targeted gene repair.
    Type: Application
    Filed: February 12, 2010
    Publication date: December 1, 2011
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Audrey McConnell-Smith, Barry L. Stoddard
  • Patent number: 8067152
    Abstract: A method of detecting whether a subject is afflicted with or at increased risk of developing liver cancer is carried out by detecting cleavage of a marker in a sample such as a blood sample from the subject. Suitable markers include but are not limited to, calreticulin, calreticulin precursor, protein disulfide isomerase family A member 3 (PDIA3), and cleavage products thereof. The cleavage, or extent of cleavage, can be as compared to that found in a control sample.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: November 29, 2011
    Assignee: The Fred Hutchinson Cancer Research Center
    Inventor: Laura Beretta
  • Patent number: 8052369
    Abstract: Device for storing tubular on a drilling and/or production installation, comprising a shaft (8, 9, 10, 11) to accommodate a plurality of tubular in a substantially vertical position and a guide (15, 22) that is moveable above the shaft (8, 9, 10, 11). The device comprises means for displacing the guide (15, 22) in a substantially horizontal plane to a position above a selected one of all the tubular in the shaft. Also described are a catwalk (12) configured to displace the tubular in an axial direction through a V-door in the derrick (5), and which is further configured to be tilted into a substantially vertical position to receive or deliver a tubular, and a knuckle boom crane (7) with a grapple (27) that is adapted to grip an upper end of a substantially vertical tubular and carry the tubular in a substantially vertical orientation.
    Type: Grant
    Filed: September 25, 2006
    Date of Patent: November 8, 2011
    Assignee: Fred Olsen Energy ASA
    Inventors: Ola Often, Sondre Hagen
  • Publication number: 20110263952
    Abstract: An incontinence management system for monitoring wetness in one or more absorbent articles, includes input for receiving one or more sensor signals indicative of a presence of wetness in an absorbent article, processor for processing the one or more sensor signals and for performing an analysis of the signals to characterise wetness events occurring in an absorbent article and user interface for communicating with a user of the system. A mathematical model is used to characterise wetness events, receiving as inputs variables derived from sensor signals and optionally, patient and demographic data. The mathematical model can be configured and/or re-configured utilising observation data obtained while monitoring a patient for wetness. A diaper for use with such as system is also disclosed.
    Type: Application
    Filed: June 10, 2011
    Publication date: October 27, 2011
    Applicant: FRED BERGMAN HEALTHCARE PTY LTD
    Inventors: Frederick Bergman, Ari Bergman, David Albert Barda, Daniel Weinstock, Remi Guibert, Maria C. Rodda, Guy Eitzen
  • Publication number: 20110250146
    Abstract: The present invention provides nanoparticles having a core comprising a magnetic material and having a surface, where the surface may be operatively linked to an antigenic peptide-major histocompatibility complex (MHC) monomer. The antigenic peptide-MHC monomer may then be recognized by a T cell receptor. These nanoparticles may further comprise a signal-generating label, such as a fluorophore. Methods employing nanoparticles of the present invention may involve magnetic resonance imaging and/or fluorescence detection, such that cell imaging and localization are performed.
    Type: Application
    Filed: October 8, 2010
    Publication date: October 13, 2011
    Applicants: FRED HUTCHINSON CANCER RESEARCH CENTER, UNIVERSITY OF WASHINGTON
    Inventors: Miqin Zhang, Jonathan Whitney Gunn, Cassian Yee
  • Publication number: 20110230839
    Abstract: A fluid delivery device includes an array of needles, each in fluid communication with a respective reservoir. Respective actuators are coupled so as to be operable to drive fluid from the reservoirs via needle ports. Each needle can have a plurality of ports, and the ports can be arranged to deliver a substantially equal amount of fluid at any given location along its length. A driver is coupled to the actuators to selectively control the rate, volume, and direction of flow of fluid through the needles. The device can simultaneously deliver a plurality of fluid agents along respective axes in solid tissue in vivo. If thereafter resected, the tissue can be sectioned for evaluation of an effect of each agent on the tissue, and based on the evaluation, candidate agents selected or deselected for clinical trials or therapy, and subjects selected or deselected for clinical trials or therapeutic treatment.
    Type: Application
    Filed: March 15, 2011
    Publication date: September 22, 2011
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: S. Bahram Bahrami, Mandana Veiseh, James Olson
  • Publication number: 20110224911
    Abstract: In one aspect, the invention provides methods for determining the contributions of canid populations to a canid genome. The methods comprise the steps of: (a) obtaining the identity of one or both alleles in a test canid genome for each of a set of markers; and (b) determining the contributions of canid populations to the test canid genome by comparing the alleles in the test canid genome to a database comprising canid population profiles, wherein each canid population profile comprises genotype information for the set of markers in the canid populations.
    Type: Application
    Filed: March 2, 2011
    Publication date: September 15, 2011
    Applicant: FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Elaine Ostrander, Leonid Kruglyak, Heidi G. Parker, Lisa V. Kim, Matthew Stephens, Tiffany B. Malek, Nathan B. Sutter, Scott Carlson
  • Patent number: 8014957
    Abstract: The invention provides molecular markers that are associated with the progression of chronic myeloid leukemia (CML), and methods and computer systems for monitoring the progression of CML in a patient based on measurements of these molecular markers. The present invention also provides CML target genes, and methods and compositions for treating CML patients by modulating the expression or activity of these CML target genes and/or their encoded proteins. The invention also provides genes that are associated with resistance to imatinib mesylate (Gleevecâ„¢) treatment in CML patients, and methods and compositions for determining the responsiveness of a CML patient to imatinib mesylate treatment based on measurements of these genes and/or their encoded proteins. The invention also provides methods and compositions for enhancing the effect of Gleevecâ„¢ by modulating the expression or activity of these genes and/or their encoded proteins.
    Type: Grant
    Filed: December 14, 2006
    Date of Patent: September 6, 2011
    Assignees: Fred Hutchinson Cancer Research Center, Rosetta Inpharmatics LLC
    Inventors: Jerald P. Radich, Hongyue Dai, Mao Mao, Janell M. Schelter, Peter S. Linsley
  • Patent number: 7993681
    Abstract: The present invention concerns the use of oxygen antagonists for inducing stasis in tissue, including all or part of organs. It includes methods and apparatuses for achieving stasis in tissue, so as to preserve and/or protect them. In specific embodiments, preservation methods and apparatuses for preserving tissue for transplantation purposes is provided.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: August 9, 2011
    Assignee: Fred Hutchinson Cancer Research Center
    Inventor: Mark B. Roth
  • Patent number: 7977529
    Abstract: An incontinence management system for monitoring wetness in one or more absorbent articles, includes input for receiving one or more sensor signals indicative of a presence of wetness in an absorbent article, processor for processing the one or more sensor signals and for performing an analysis of the signals to characterise wetness events occurring in an absorbent article and user interface for communicating with a user of the system. A mathematical model is used to characterise wetness events, receiving as inputs variables derived from sensor signals and optionally, patient and demographic data. The mathematical model can be configured and/or re-configured utilising observation data obtained while monitoring a patient for wetness. A diaper for use with such as system is also disclosed.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: July 12, 2011
    Assignee: Fred Bergman Healthcare Pty Ltd.
    Inventors: Frederick Bergman, Ari Bergman, legal representative, David Albert Barda, Daniel Weinstock, Remi Guibert, Maria C. Rodda, Guy Eitzen
  • Patent number: 7972791
    Abstract: The present invention provides a novel method for specifically isolating and separating large segments of genomic DNA that can subsequently be used to determine a genomic haplotype. The invention relies on using a solid phase having a flat surface arrayed with oligonucleotides designed to specifically hybridize to each particular haplotype of an individual sample, e.g., oligonucleotides designed to specifically hybridize with each of the two HLA-B haplotypes, HLA-A, HLA-C, HLA-DR, HLA-DQ, and the like. The genomic DNA is contacted and hybridized to the arrayed oligonucleotides to form a genomic DNA/oligonucleotide complex. The excess genomic DNA is washed away and the haplotype separated genomic DNA is denatured from the oligonucleotide probe and collected. The method of the present invention allows for the separation of genomic DNA fragments of between approximately 2 to about 4 megabases (Mb).
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: July 5, 2011
    Assignees: Fred Hutchinson Cancer Research Center, Institute for Systems Biology
    Inventors: Effie W. Petersdorf, Zhen Guo, Leroy Hood
  • Patent number: 7959916
    Abstract: The present invention relates to methods of treating immune disorders and cancers. In particular the invention provides methods of inhibiting the negative immunomodulatory effects of ERp-5 on T cells and dendritic cells, in conjunction with other surface receptors.
    Type: Grant
    Filed: April 23, 2008
    Date of Patent: June 14, 2011
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Thomas Spies, Veronika Groh-Spies
  • Publication number: 20110135756
    Abstract: The invention provides compounds, compositions and methods that can be used for the attenuation of damage to sensory hair cells and symptoms thereof. More particularly, the invention identifies drugs that can be used to protect sensory hair cells from ototoxic medications, noise-induced damage and age-related loss.
    Type: Application
    Filed: December 8, 2010
    Publication date: June 9, 2011
    Applicants: University of Washington, Fred Hutchinson Cancer Research Center
    Inventors: Kelly N. Owens, Anna L. Corke, Henry C. Ou, Edwin W. Rubel, David W. Raible, Julian A. Simon
  • Publication number: 20110088106
    Abstract: Hypercellular nonhuman organisms have functionally inactivated expression of a cyclin inhibitor gene, especially p27. The growth rate of nonhuman organisms are increased such that a desired size is attained more quickly than as compared to nonvariant organisms. Inhibitors of the p27 cyclin dependent kinase inhibitor protein or sequences encoding the protein modulate vertebrate cell cycle progression and increase the proportion of dividing cells to non-dividing cells in a population of treated cells. As the proportion of dividing cells increases, the cell population, e.g., hematopoietic progenitor (stem) cells, is more efficiently used for gene therapy applications. Transgenic animals and plants, and knockout alleles are provided.
    Type: Application
    Filed: July 14, 2009
    Publication date: April 14, 2011
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: James M. Roberts, Steven R. Coats, Matthew L. Fero
  • Publication number: 20110059012
    Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.
    Type: Application
    Filed: January 28, 2009
    Publication date: March 10, 2011
    Applicant: Fred Hutchinson Cancer Research Center
    Inventors: Cameron J Turtle, Stanley R. Riddell